In this study of 186,867 patients with HR-positive, HER2-negative invasive breast cancer who underwent 21-gene RS testing in the NCDB, we found that patients with ILC have higher rates of discordant clinical and genomic risk than those with IDC. The gene discussed is ERBB2; the disease is invasive breast carcinoma.